Ronald A Fleming

US Patent:

6670341, Dec 30, 2003

Filed:

Oct 19, 2000

Appl. No.:

09/693658

Inventors:

Louis S. Kucera - Pfafftown NC
Ronald A. Fleming - Cary NC
Khalid S. Ishaq - Chapel Hill NC
Gregory L. Kucera - Winston-Salem NC

Assignee:

Wake Forest University Health Sciences - Winston-Salem NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

A61K 3166

US Classification:

514 77, 536 261, 536 262, 536 2621, 536 2622, 536 2623, 536 267, 536 268, 536115, 536117, 536120

Abstract:

The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i. e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e. g. nucleoside analogue, protease inhibitor, etc. ) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e. g.

US Patent:

7026469, Apr 11, 2006

Filed:

Apr 27, 2001

Appl. No.:

09/844201

Inventors:

Louis S. Kucera - Pfafftown NC, US
Ronald A. Fleming - Cary NC, US
Khalid S. Ishaq - Chapel Hill NC, US
Gregory L. Kucera - Winston-Salem NC, US

Assignee:

Wake Forest University School of Medicine - Winston-Salem NC
University of North Carolina at Chapel - Chapel Hill NC

International Classification:

C07H 17/00
A61K 31/70

US Classification:

536 261, 536 262, 536 2621, 536 2622, 536 2623, 536 267, 536 268, 536116, 536120

Abstract:

The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i. e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e. g. nucleoside analogue, protease inhibitor, etc. ) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds, which comprise an alkyl lipid or phospholipid moiety covalently conjugated with a therapeutic agent (e. g.

US Patent:

7309696, Dec 18, 2007

Filed:

Dec 30, 2003

Appl. No.:

10/748738

Inventors:

Louis S. Kucera - Pfafftown NC, US
Ronald A. Fleming - Cary NC, US
Khalid S. Ishaq - Chapel Hill NC, US
Gregory L. Kucera - Winston-Salem NC, US

Assignee:

Wake Forest University - Winston-Salem NC
University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

A01N 43/04
A61K 31/70
C07H 19/00
C07H 19/048

US Classification:

514 51, 514 43, 514 49, 514 50

Abstract:

The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i. e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e. g. nucleoside analogue, protease inhibitor, etc. ) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e. g.

US Patent:

7638528, Dec 29, 2009

Filed:

Apr 6, 2006

Appl. No.:

11/398529

Inventors:

Louis S. Kucera - Pfafftown NC, US
Ronald A. Fleming - Cary NC, US
Khalid S. Ishaq - Chapel Hill NC, US
Gregory L. Kucera - Winston-Salem NC, US

Assignee:

Wake Forest University School of Medicine - Winston-Salem NC
The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514283, 514 77, 514423, 546 41, 546 48

Abstract:

The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i. e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e. g. nucleoside analogue, protease inhibitor, etc. ) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e. g.

US Patent:

8138200, Mar 20, 2012

Filed:

Dec 2, 2009

Appl. No.:

12/629387

Inventors:

Louis S. Kucera - Pfafftown NC, US
Ronald A. Fleming - Cary NC, US
Khalid S. Ishaq - Chapel Hill NC, US
Gregory L. Kucera - Winston-Salem NC, US

Assignee:

Wake Forest University - Winston-Salem NC
University of North Carolina-Chapel Hill - Chapel Hill NC

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514283, 514 77, 514423, 546 41, 546 48

Abstract:

The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i. e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e. g. nucleoside analogue, protease inhibitor, etc. ) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e. g.

US Patent:

20050187191, Aug 25, 2005

Filed:

Feb 20, 2004

Appl. No.:

10/781894

Inventors:

Louis Kucera - Pfafftown NC, US
Khalid Ishaq - Chapel Hill NC, US
Ronald Fleming - Cary NC, US
Jan Hess - Hurdle Mills NC, US
Yunsheng Huang - Apex NC, US
Russ Read - Rural Hall NC, US
Phillip Furman - Durham NC, US

International Classification:

A61K031/685

US Classification:

514078000, 514114000

Abstract:

The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

US Patent:

20050187192, Aug 25, 2005

Filed:

Feb 20, 2004

Appl. No.:

10/783927

Inventors:

Ronald Fleming - Cary NC, US
Jan Hes - Hurdle Mills NC, US
Yunsheng Huang - Apex NC, US
Russ Read - Rural Hall NC, US
Khalid Ishaq - Chapel Hill NC, US
Louis Kucera - Pfaffown NC, US
Phillip Furman - Durham NC, US

International Classification:

A61K031/685

US Classification:

514078000, 514114000

Abstract:

Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a , herpes virus and/or , and in particular SARS-CoV, or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

US Patent:

20100273740, Oct 28, 2010

Filed:

Nov 23, 2009

Appl. No.:

12/623612

Inventors:

Ronald A. FLEMING - Cary NC, US
Jan V. Hes - Hurdle Mills NC, US
Yunsheng Huang - Apex NC, US
Russ H. Read - Rural Hall NC, US
Khalid S. Ishaq - Chapel Hill NC, US
Louis S. Kucera - Pfaffown NC, US
Phillip A. Furman - Durham NC, US

International Classification:

A61K 31/661
A61P 31/22
A61P 31/14

US Classification:

514 77

Abstract:

Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.